Market Overview

Cerenis Announces Financing from Investment Funds, Management, Its Board of Directors and Its Oncology Scientific Advisory Board

Share:

Regulatory News:

Cerenis Therapeutics (Paris:CEREN) (FR0012616852 –
CEREN – PEA PME eligible)
, an international biopharmaceutical
company dedicated to the discovery and development of HDL-based
innovative therapies for treating cardiovascular, metabolic diseases,
and new HDL-based vectors for the targeted drug delivery in the oncology
field announces a capital increase of more than one million euros for
the financing of its immuno-oncology activities.

Terms of issuance

The Company is issuing 638,753 new shares at a price of 1.78 euros per
share (a discount of 5% compared to the weighted average of the 10
trading days preceding the decision of the Board of Directors dated of
July 16, 2018 subdelegating its jurisdiction).

This issuance is part of a capital increase with cancellation of
preferential subscription rights for the benefit of persons belonging to
specific categories1, decided today by the Chief Executive
Officer, acting on the delegation of authority from the Board of
Directors on the basis of the prior delegation granted by the General
Meeting of 25 June 2018 pursuant to the terms of its twenty-sixth
extraordinary resolution.

The total amount of the capital increase is 1,136,980.34 euros (of which
31,937.65 euros in nominal value, together with an issue premium of
1,105,042.69 euros).

The number of shares thus issued represents approximately 3.37% of the
number of shares outstanding (post-issue). By way of illustration, a
shareholder who held a number of shares representing 1% of the share
capital of Cerenis prior to the issue, now represents 0.97% of the share
capital.

_______________
1 The categories of persons targeted
within the frame of this issuance are:
(i) Natural or legal persons
(including companies), investment companies, trusts, investment funds or
other investment vehicles, whatever their form, under French or foreign
law, investing on a regular basis in the pharmaceutical, biotechnology
sectors, in cardiovascular and metabolic diseases, or medical
technologies; and or
(ii) Companies, institutions or entities in
any form, French or foreign, exercising a significant part of their
activity in these areas; and or
(iii) French or foreign investment
service providers with an equivalent status capable of guaranteeing the
completion of a capital increase intended to be placed with the persons
referred to in (i) and (ii) above and, in this framework, to subscribe
to securities issued; and or
(iv) Company officers (including
managers), the Board of Directors, employees and members of any
committee of the company or one of its subsidiaries and any person
(natural or legal) bound by a service or consulting contract to the
Company or any of its subsidiaries.

The issuance does not require a prospectus submitted for approval by the
AMF.

The new shares will have current privileges, will be assimilated to the
old shares, and will enjoy the same rights. They will be subject to all
the statutory provisions and will be admitted to trading on Euronext on
the same quotation line as the existing shares.

Following this capital increase, the number of shares making up the
capital of the Company amounts to 18,947,016 representing as many actual
voting rights.

Objectives of the fundraising

The proceeds of the issuance follow the strategic decision, announced by
the company at the end of 2017, to leverage and value its skills and
know-how in HDL and HDL mimetics, its intellectual property, and its
unique clinical experience with HDL mimetics.

The capital increase of more than one million euros is intended to
finance the announced development of the HDL platform with in particular
the launch of two programs (CER-320 and CER-350) in immuno-oncology.
This is in line with previous initiatives (the acquisition of Lypro's
assets, the "HDL Initiative", a strategic partnership for the
development of new pharmaceuticals with the University of North Texas
Health Science Center, the constitution of the SAB in oncology, and the
encouraging results of the TARGET study).

This operation reflects the significant confidence of the management,
and the Scientific advisory Board in Oncology in Cerenis and its
programs in Oncology.

Risk factors

The risk factors are described in the 2017 Registration Document
(Chapter 4) registered by the AMF under number R.18-0022 on 23 April
2018 and available on the Company's website www.cerenis.com
and that of the AMF www.amf-france.org.

About CERENIS: www.cerenis.com

CERENIS Therapeutics is an international biopharmaceutical company
dedicated to the discovery and development of innovative lipid
metabolism therapies for the treatment of cardiovascular, metabolic
diseases, and HDL platform technologies. HDL is the primary mediator of
the reverse lipid transport, or RLT, the only natural pathway by which
excess lipids are removed from arteries and transported to the liver for
elimination from the body.

In addition to advancing HDL technologies for drug delivery, CERENIS is
developing a portfolio of lipid metabolism therapies, including HDL
mimetics for patients with genetic HDL deficiency, as well as drugs
which increase HDL for patients with a low number of HDL particles to
treat atherosclerosis and associated metabolic diseases including
Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic
Steato-Hepatitis (NASH). Leveraging its expertise, Cerenis is developing
the first platform for the targeted drug delivery by HDL dedicated to
the field of oncology (immuno-oncology and chemotherapy).

CERENIS is well positioned to become one of the leaders in the HDL
therapeutic market, with a broad portfolio of programs in development.

About Targeted HDL Drug Delivery

HDL particles, loaded with an active agent, hold the promise to target
and selectively kill malignant cells while sparing healthy ones. A wide
variety of drugs can be embedded in these particles targeting markers
specific to cancer cells and bring these potent drugs to their intended
site of action, with lowered systemic toxicity. Cerenis intends to
develop the first HDL-based targeting drug delivery platform dedicated
to the oncology market, including immuno-oncology and chemotherapy.

Financial Calendar

2018 Half year Results: September 11th, 2018

View Comments and Join the Discussion!